Argos’ internal management team and Board of Directors have extensive experience with both the science and business of biotechnology, ranging from preclinical to clinical development, product launch and marketing, to manufacturing commercial products.
Jeffrey D. Abbey has served as our President and Chief Executive Officer and a member of our board of directors since February 2010. Mr. Abbey served in various other positions at our company from September 2002 to February 2010, including as our Vice President of Business Development from February 2004 to January 2009 and as our Chief Business Officer from January 2009 to February 2010. Prior to joining us, Mr. Abbey served as Vice President of Business Development and Finance at Internet Appliance Network, an information technology company, from 1999 to 2001. Mr. Abbey was a partner at Eilenberg and Krause, LLP, a corporate law firm, from 1994 to 1999. Mr. Abbey received an A.B. in mathematical economics from Brown University and an M.B.A. and J.D. from the University of Virginia.
Charles A. Nicolette, Ph.D. has served as our Chief Scientific Officer since December 2007 and as our Vice President of Research and Development since December 2004. Dr. Nicolette served as our Vice President of Research from July 2003 to December 2004. Prior to joining us, Dr. Nicolette served in various positions at Genzyme Molecular Oncology, Inc., a biotechnology company, from 1997 to 2003, most recently as Director of Antigen Discovery. Dr. Nicolette received a B.S. from the State University of New York at Stony Brook and a Ph.D. in biochemistry and cellular and developmental biology from the State University of New York at Stony Brook, completing his doctoral dissertation and post-doctoral fellowship at Cold Spring Harbor Laboratory.
Dr. Katz comes to Argos with more than 20 years of experience in healthcare finance and corporate development. Most recently, Dr. Katz served as chief financial officer for Viamet Pharmaceuticals, Inc. Previously, Dr. Katz served as chief financial officer for Icagen, Inc., where he was instrumental in the company’s initial public offering and subsequent financings, the formation of several strategic collaborations, and the company’s sale to Pfizer. Prior to Icagen, Dr. Katz worked as a vice president in the healthcare group at Goldman, Sachs & Company, where he executed a broad range of transactions, including equity and debt financings, mergers and acquisitions, and corporate restructurings. Dr. Katz received his A.B. magna cum laude from Harvard University, his M.D. from the Stanford University School of Medicine and his M.B.A. from Harvard Business School, where he graduated as a Baker Scholar.
Lee F. Allen, M.D., Ph.D., has served as our Chief Medical Officer since January 2016. Prior to joining Argos, Dr. Allen served as Chief Medical Officer at Spectrum Pharmaceuticals, a commercial stage biotechnology company focused on Hematology/Oncology since March 2013. Prior to joining Spectrum, Dr. Allen held executive level positions with AMAG Pharmaceuticals from August 2007 until March 2013, most recently serving as Chief Medical Officer and Executive Vice President, Medical Development. Prior to that, Dr. Allen served as Cambridge Site Head and Vice President of Oncology Clinical Research & Development, Wyeth Research from April 2003 until August 2007. In addition, he has also held executive positions in Pfizer and BASF’s Knoll Pharmaceuticals Hematology/Oncology groups. In addition, Dr. Allen has served in clinical leadership roles in the Division of Hematology/Oncology at the University of Utah Health Sciences’ Huntsman Cancer Institute and Duke University Medical Center. He holds a Ph.D. in pathology and an M.D. from the University of Medicine and Dentistry of New Jersey, and trained in Internal Medicine and Hematology/Oncology at the Duke University Medical Center.
Lori R. Harrelson has served as our Vice President of Finance since July 2011. Ms. Harrelson served as our Director of Finance and Accounting from January 2007 to July 2011 and as our Director of Accounting and Financial Reporting from September 2004 to January 2007. Prior to joining us, Ms. Harrelson served as Finance Manager at LipoScience, Inc., a diagnostic company, from 2001 to 2004. Ms. Harrelson received a B.S. in finance from East Carolina University and is a C.P.A.
John D. Menditto has served as Vice President of Corporate Communications and Investor Relations since May 2015. Prior to joining us, he spent a number of years as a communications consultant, including, more recently, as Head of Investor Relations, The Americas, at the Imagination Group. He served as Director, Investor Relations in North America at Novartis Corporation, from 2001 until 2008 and Senior Global Director of Investor Relations at Medco Health Solutions, from 2008 until 2009. He holds a B.A. in public relations from Susquehanna University in Selinsgrove, Pennsylvania.
Joan C. Winterbottom, has served as our Chief Human Resources Officer since February 2015. Prior to joining Argos Therapeutics she served as Senior Vice President, Human Resources at Amicus Therapeutics, Inc., from 2012 to 2014 and as Senior Vice President, Human Resources at Savient Pharmaceuticals, Inc., from 2011 to 2012. Earlier Ms. Winterbottom held human resources leadership roles at Johnson & Johnson from 2001 to 2011, most recently as Vice President of Human Resources for the Global Over-the-Counter/Nutritionals/Wellness and Prevention global business unit and before that as Vice President of Human Resources for J&J’s McNeil Consumer Healthcare Company. She also served as Global Director, Head of Human Resources for the J&J Biologics, Immunology, and Oncology Research & Development unit, Centocor. Ms. Winterbottom earned a B.S. in business and economics from Lehigh University, and a graduate level certificate in organization development from Saint Joseph’s University.